Federal court strikes down Trump-era abortion pill restrictions as unlawful
A Virginia federal judge ruled that Trump administration restrictions on mifepristone were arbitrary and capricious, ordering regulators to reconsider rules affecting the widely used abortion medication that has been deemed safe for over two decades.
Federal court strikes down Trump-era abortion pill restrictions as unlawful
A federal court in Virginia has struck down restrictions on the abortion pill mifepristone imposed by the Trump administration, ruling they are unlawful and must be reconsidered by regulators.
Judge Robert S. Ballou of the U.S. District Court for the Western District of Virginia entered his ruling Thursday, finding that new safety requirements were "arbitrary and capricious" given the Food and Drug Administration's consistent determination over a quarter century that mifepristone is safe and effective.
The case, formally titled Whole Woman's Health Alliance v. FDA, was brought in May 2023 by the nonprofit Center for Reproductive Rights on behalf of abortion providers including Whole Woman's Health Alliance clinics in Virginia, Trust Women in Kansas, and All Families Healthcare and Blue Mountain Clinic in Montana.
Contested Safety Requirements
At the center of the dispute are rules known as Risk Evaluation and Mitigation Strategies, or REMS, a drug safety program framework the FDA established in 2007 for medications requiring additional oversight to ensure benefits outweigh risks.
The Trump administration's new restrictions require prescribers to register with the manufacturer, creating what advocates describe as a national database of abortion providers that could pose safety risks for doctors. Additional rules mandate that pharmacies obtain special certification and maintain detailed records, while patients must review counseling materials that critics have called inaccurate.
Judge Ballou ordered the administration to reconsider the restrictions but stopped short of voiding them entirely or finding that the FDA had acted illegally in principle by attempting to impose safety requirements.
Decades of Safety Findings
The FDA first approved mifepristone on September 28, 2000, following a 54-month review period for medical termination of pregnancy up through seven weeks of gestation. Since then, the agency has repeatedly affirmed the medication's safety profile, extending the approved gestational limit to ten weeks in 2016 and approving a generic version in April 2019.
A Johns Hopkins study published in January 2026 reviewed 264 internal FDA documents totaling 5,239 pages related to mifepristone safety from 2011 to 2023. The research found that FDA decisions were consistently based on safety considerations and evidence.
In December 2021, the FDA permanently revised its policy to allow clinicians to prescribe mifepristone via telehealth and permit dispensing by mail or pharmacies, eliminating the previous in-person requirement. This change was formalized in a 2023 REMS update. By the last quarter of 2024, one in four abortions in the United States were provided via telehealth, representing a significant shift in how abortion care is delivered.
Parallel Legal Battles
The Virginia ruling comes as a separate case proceeds through the Fifth Circuit Court of Appeals, where Louisiana is asking the FDA to reimpose a ban on patients receiving mifepristone by mail or through pharmacies after virtual medical visits.
On May 1, 2026, the Fifth Circuit temporarily banned nationwide mailing of mifepristone, but the Supreme Court stayed that order on May 14, maintaining current access rules while litigation continues. The case is now back at the appeals court for full briefings and could eventually return to the Supreme Court.
Nancy Northup, CEO of the Center for Reproductive Rights, called the Virginia decision
"a win for science."
Mifepristone is used as part of a two-pill combination for abortion and is also routinely prescribed to manage miscarriages. Since 2023, it has accounted for 63 percent of all abortions in the United States.
The FDA has separately ordered its own review of abortion pill regulations as legal challenges to medication abortion access continue across multiple jurisdictions.
